AAA237, an SKP2 inhibitor, suppresses glioblastoma by inducing BNIP3-dependent autophagy through the mTOR pathway.

"Declarations Ethics approval and consent to participateApproval for this research was obtained from the ethics committee for laboratory animal care and the Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, located in Beijing, China. Consent for publicationThe manuscript has been approved for submission by the authors. Competing interestsThe authors declare that they have no conflicts of interest. Competing interests The authors declare that they have no conflicts of interest."

"Funding This work was supported by Beijing Natural Science Foundation (7212157, China), CAMS Innovation Fund for Medical Sciences (2021-I2M-1-029 and 2022-12M-JB-011, China). This work was also supported by National Natural Science Foundation of China (81703536, 82073311, China)."